MedTrace Logo

Effects of MDMA and Methylphenidate on Social Cognition

NCT01616407 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-12-11

No results posted yet for this study

Summary

The purpose of this study is to assess and compare the effects of a single dose of 3,4-methylenedioxymethamphetamine (MDMA)and methylphenidate (MPH) on emotional and social cognition in healthy subjects. The investigators hypothesize that MDMA enhances affective perception for positive and impairs perception for negative emotional stimuli compared to placebo or MPH.

Conditions

  • Social Cognition

Interventions

DRUG

3,4-Methylenedioxymethamphetamine

75 mg per os, single dose

DRUG

Methylphenidate

40 mg per os, single dose

DRUG

Placebo

capsules identical to MDMA or methylphenidate but containing no active drug

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Matthias E Liechti, MD · University Hospital, Basel, Switzerland

Study Design

Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2012-12-31
Completion
2013-04-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01616407 on ClinicalTrials.gov